Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Digestive & weight
What should I know about BPC-157 dosage?
No standard BPC-157 dosage has been set for people. See the reported 200-500 mcg daily range, the doses studies tested, and what to check on a product.
Quick answer
No standard BPC-157 dosage has been established for people. Reported off-label protocols commonly cite 200-500 mcg per day by subcutaneous injection or by mouth, a range extrapolated informally from rodent doses. These are reported practice patterns rather than a standardized dose. Animal safety studies spanned 6 mcg/kg to 20 mg/kg. Three small peer-reviewed human studies covering 30 people tested fixed doses of 2-20 mg. BPC-157 is not an FDA-approved drug, has no established labeled route, and is prohibited in sport under WADA rules.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
Is there a standard BPC-157 dose?
No standard BPC-157 dosage has been established for people. Validated human dosing and long-term safety data1 are not yet available. Most BPC-157 findings come from laboratory and animal research. Peer-reviewed human research includes three small studies covering 30 people2. They reported symptom improvement in most participants, with no treatment-related adverse events.
BPC-157 is not part of any FDA-approved drug3 and has no USP or NF monograph, the official quality standard for a drug ingredient. No drug label sets a BPC-157 dose, route, or schedule.
Without a label, BPC-157 dose figures come from what users report.
What BPC-157 doses are reported?
Reported off-label BPC-157 protocols commonly cite 200-500 mcg per day4, given by subcutaneous (under-the-skin) injection or by mouth. These are reported practice patterns rather than a standardized dose.
The reported BPC-157 range was extrapolated informally from rodent doses4, without formal scaling between species. Dosing frequency and duration have not been established5, so the prescribing clinician sets the schedule.
Study-tested BPC-157 doses add a second record.
What BPC-157 doses have studies tested?
Most BPC-157 dosing studies gave animals doses by body weight6, while three peer-reviewed human studies used fixed doses of 2-20 mg.
Animal safety studies of BPC-157 spanned 6 mcg/kg to 20 mg/kg6 across intramuscular, intraperitoneal (into the abdominal cavity), intravenous, and oral routes. Musculoskeletal animal studies usually gave BPC-157 once daily, from a single dose up to 90 days of dosing7. FDA called the human BPC-157 doses it reviewed likely exploratory3, with short courses and small groups.
| Study | Species or population | Route | Dose and unit | Duration |
| Achilles tendon study | Rats | Intraperitoneal (into the abdominal cavity) | 10 mcg/kg, 10 ng/kg, or 10 pg/kg8 body weight | Once daily, up to 14 days |
| Pharmacokinetic study | Rats and dogs | Intravenous and intramuscular | Single doses of 20-500 mcg/kg in rats9 and 6-150 mcg/kg in dogs; repeat doses of 100 mcg/kg in rats and 30 mcg/kg in dogs | Single dose, or once daily for 7 days |
| Preclinical safety program10 | Rats and dogs | Intramuscular | 0.2, 1, or 4 mg/kg per day3 in rats; 0.1, 0.5, or 2 mg/kg per day in dogs | Daily for 28 days |
| Knee pain chart review11 | 16 people with knee pain followed up (17 charts reviewed) | Intra-articular (into the joint) injection | 2-4 mg3 | 1-2 injections |
| Bladder pain pilot | 12 women with interstitial cystitis | Injection into the bladder wall during cystoscopy | 10 mg total12 | 1 procedure |
| Intravenous safety pilot | 2 healthy adults | Intravenous infusion | 10 mg on day 1, then 20 mg13 on day 2 | 2 days |
| Rotator cuff repair pilot trial | Adults after arthroscopic rotator cuff repair | Subcutaneous | Dose amount not listed in the registry | Planned once daily for 90 days14; not yet recruiting, no results posted as of November 2026 |
| Oral tablet trial, Phase 1 | 42 healthy volunteers (planned enrollment) | Oral tablet | Planned single doses of 1, 3, or 6 mg15, then 3 mg every 8 hours | Planned 2 weeks; status unknown since 2015, no results posted |
Per-kilogram BPC-157 doses in animals do not translate directly into human doses4, so no weight chart for people follows from them. BPC-157 products add another variable, since they differ in form and strength.
What forms does BPC-157 come in?
BPC-157 is sold as injections, capsules, oral sprays, and nasal sprays3. FDA found no human absorption data3 for oral, subcutaneous, nasal, or skin use of BPC-157.
BPC-157 product strengths show what is sold, not a tested dose. A different route can change how much BPC-157 is absorbed. Research or experience with one route does not automatically describe another.
What to check on a BPC-157 product depends on its form.
| Form | What to check |
| Injection | Identity, purity, and concentration1; vial strength (freeze-dried 6 mg and 10 mg vials3); sterility, bacterial endotoxins, and particles3; storage; and who prepared the product |
| Capsule or oral spray | The exact BPC-157 form (free base or acetate salt), the strength in micrograms (500 mcg products sold3), and what supports its stability and absorption |
| Nasal spray | Whether the research being cited used a nasal route or a different product |
Reconstitution means mixing freeze-dried BPC-157 with a specified amount of bacteriostatic water. A prescribing clinician sets the target dose, which the vial's strength and water volume turn into syringe units. Anti-doping rules add a separate limit on BPC-157 for competitive athletes.
The 2026 Prohibited List from the World Anti-Doping Agency (WADA) names BPC-157 as a non-approved substance (class S0), banned at all times16. Athletes subject to drug testing can face sanctions for BPC-157 use and should check current WADA and league rules.
Getting BPC-157 in 2026
Superpower will offer BPC-157 formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will decide whether BPC-157 belongs in each person's health care. The Superpower peptide waitlist is open now.
BPC-157 has not been approved by FDA as a drug. In October 2026, the Department of Health and Human Services announced it does not intend to take enforcement action17 against state-licensed pharmacies compounding six peptides, BPC-157 among them, while the 503A Bulks List (the list of ingredients pharmacies may use in compounding) is finalized. Conditions of the interim policy18 include a patient-specific prescription and ingredients from FDA-registered facilities. A July 2026 FDA advisory committee recommendation to add BPC-157 to the list19 came first, and the rulemaking continues.